Emcure has established its presence in over 70 locations globally, with strategic partnerships with multi-national companies while offering expertise in biologics, Novel Drug Delivery Systems, APIs, chiral molecules, peptides, polymer-based chemistry, and complex products.
Emcure has established a strong presence with fast growth in Europe and Canada, led by its differentiated product portfolio.
Emcure has a widespread supply chain across 70+ countries with a key focus on LATAM, Middle East, Africa, Asia, Russia/CIS, Australia. Emcure leverages its differentiated portfolio of chirality, iron, complex injectables, next-gen ARVs with over 180 approved products and more than 1000 regulatory approvals in the RoW markets.
Emcure has a focused go-to market strategy which uses a mix of front-end presence, partnership presence and distributor model to target the different market dynamics through its diversified product portfolio.
With innovative products in the pipeline and differentiated portfolio of biologics, Emcure aims to continue to grow in the RoW market with deeper market penetration and calibrated strategy.
